USPTO reaffirms Broad Institute's CRISPR/Cas9 patent priority; Editas' licensed patents upheld

Editas Medicine, Inc.

PTAB issued third favorable decision for Broad over CVC on CRISPR/Cas9 editing in eukaryotic cells.
CVC retains the right to appeal to the U.S. Court of Appeals for the Federal Circuit.
Editas' exclusive license to the CRISPR/Cas9 patents at issue remains intact; other in-licensed patents not impacted.
CEO Gilmore O'Neill cites confidence in IP, highlighting EDIT-401 with >90% mean LDL reduction in NHPs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.